Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2011 - 2025)

Rigel Pharmaceuticals' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $1.4 million for Q3 2025.

• On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $1.4 million in Q3 2025; TTM through Sep 2025 was $1.4 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $1.4 million, changed 0.0% from the prior year.
• Current Deferred Revenue steadied at $1.4 million in Q3 2025 per RIGL's latest filing, from $1.4 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $9.5 million in Q1 2021 and bottomed at $1.4 million in Q2 2023.
• The 5-year median for Current Deferred Revenue is $1.4 million (2023), against an average of $2.2 million.
• Across the five-year window, Current Deferred Revenue jumped 362.74% in 2021 and sank 77.93% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.6 million in 2021, then tumbled by 47.27% to $1.4 million in 2022, then decreased by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
• Per Business Quant, the three latest RIGL Current Deferred Revenue figures stand at $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $1.4 million (Q1 2025).